Therefore, even though PTPH1 exerts oncogenic activity via modulation of VDR dynamics, the phosphatase may be useful as a marker for heightened breast cancer sensitivity to antihormone therapies (Table 4). The gene discussed is PTPN3; the disease is breast carcinoma.